Diabetes Pharmacotherapy in 2012: Considerations in Medication Selection

References

• . International Diabetes Federation. 2010–2012 strategy. http://atlas.idf-bxl.org/content/diabetes. Accessed April 20, 2012
   Google Scholar
• . Centers for Disease Control and Prevention. CDC National Diabetes Fact Sheet, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed April 23, 2012
   Google Scholar
• . Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8(1):29
   PubMed Web of Science ®Google Scholar
• . Nandish S, Wyatt J, Bailon O, Smith M, Oliveros R, Chilton R. Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus. Am J Cardiol. 2011;108( 3 suppl):42B–51B
   PubMedGoogle Scholar
• . International Diabetes Federation. The economic impacts of diabetes. http://www.idf.org/diabetesatlas/economic-impacts-diabetes. Accessed April 18, 2012
   Google Scholar
• . Field AE, Coakley EH, Must A, . Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161(13):1581–1586
   PubMedGoogle Scholar
• . Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemol. 1997; 146(3):214–222
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6): 540–559
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, . Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;55(6):1577–1596
   Google Scholar
• . Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795
   PubMed Web of Science ®Google Scholar
• . Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32( suppl 2):S151–S156
   PubMed Web of Science ®Google Scholar
• . Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113(12):909–915
   PubMed Web of Science ®Google Scholar
• . Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210–1214
   PubMed Web of Science ®Google Scholar
• . Mills GW, Avery PJ, McCarthy MI, . Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes. Diabetologia. 2004;47(4):732–738
   PubMedGoogle Scholar
• . Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab. 2007;5(4):237–252
   PubMed Web of Science ®Google Scholar
• . Herman MA, Kahn BB. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J Clin Invest. 2006;116(7):1767–1775
   PubMed Web of Science ®Google Scholar
• . Cusi K, Maezono K, Osman A, . Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105(3):311–320
   PubMed Web of Science ®Google Scholar
• . Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89(2): 463–478
   PubMed Web of Science ®Google Scholar
• . Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes. 2001;50( suppl 1):S118–S121
   PubMed Web of Science ®Google Scholar
• . Pagotto U. Where does insulin resistance start? The brain. Diabetes Care. 2009;32( suppl 2):S174–S177
   PubMedGoogle Scholar
• . Tschritter O, Preissl H, Hennige AM, . The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci USA. 2006;103(32): 12103–12108
   PubMedGoogle Scholar
• . Roth JD, Maier H, Chen S, Roland BL. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol. 2009;66(3):306–310
   PubMedGoogle Scholar
• . Freeman JS. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med. 2009;76( suppl 5):S12–S19
   PubMedGoogle Scholar
• . Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. 2004;53( suppl 3):S190–S196
   PubMed Web of Science ®Google Scholar
• . Dungan K, Buse JB. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clinical Diabetes. 2005;23(2):56–62
   Google Scholar
• . Schwedes U, Siebolds M, Mertes G; SMBG Study Group. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care. 2002;25(11):1928–1932
   PubMedGoogle Scholar
• . American Diabetes Association. Executive summary: standards of medical care in diabetes—2012. Diabetes Care. 2012;35( suppl 1): S11–S63
   PubMed Web of Science ®Google Scholar
• . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342(6):381–389
   PubMedGoogle Scholar
• . Burke SD, Cornell SA. Medication management in type 2 diabetes. Clinician Reviews. 2008;18:28–34
   Google Scholar
• . Cornell S, Lullo A. Getting to goal for patients with type 2 diabetes: mission possible. Diabetes Trends. 2009;21( suppl A):3–11
   Google Scholar
• . Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360–372
   PubMed Web of Science ®Google Scholar
• . Bolen S, Wilson L, Vassy J, . Comparative effectiveness and safety of oral diabetes medications for adults with type 2 diabetes. Comparative effectiveness review No. 8. Rockville, MD: Agency for Healthcare Research and Quality; 2008. www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed April 20, 2012
   Google Scholar
• . Fox CS, Coady S, Sorlie PD, . Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007;115(12):1544–1550
   PubMed Web of Science ®Google Scholar
• . Vibreti G, Kahn SE, Greene DA, . A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide and metformin on recently diagnosed type 2 diabetes. Diabetes Care. 2002;25(10):1737–1743
   PubMedGoogle Scholar
• . Dormandy J, Charbonnel B, Eckland D, . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005; 366(9493):1279–1289
   PubMed Web of Science ®Google Scholar
• . Mazzone T, Meyer PM, Feinstein SB, . Effect of pioglitazone compared with glimepiride on carotid intima-media cardiovascular system thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296(21):2572–2581
   PubMed Web of Science ®Google Scholar
• . Mateo JF, Gil—Guillen VF, Mateo E, Orozco D, Carbayo JA, Merino J. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract. 2006;60(4):422–428
   PubMedGoogle Scholar
• . Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122( 6 suppl):S3–S10
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705
   PubMed Web of Science ®Google Scholar
• . Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2009;43(9):1433–1444
   PubMedGoogle Scholar
• . Blevins T, Pullman J, Malloy J, . DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–1310
   PubMed Web of Science ®Google Scholar
• . Vilsboll T, Zdravkovic M, Le—Thi T, . Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care. 2007;30(6):1608–1610
   PubMed Web of Science ®Google Scholar
• . Garber A, Henry R, Ratner R, . Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med. 2009;122( 6 suppl):S37–S50
   PubMed Web of Science ®Google Scholar
• . Kim D, Macconell L, Zhuang D, . Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487–1493
   PubMed Web of Science ®Google Scholar
• . Buse JB, Rosenstock J, Sesti G, . Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47
   PubMed Web of Science ®Google Scholar
• . Herman GA, Stevens C, Van DK, . Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase I V, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675–688
   PubMed Web of Science ®Google Scholar
• . Gallwitz B. New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. Diabetes Metab Syndr Obes. 2010;3:117–124
   PubMedGoogle Scholar
• . Heise T, Graefe—Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11(8):786–794
   PubMed Web of Science ®Google Scholar
• . Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001;(50):1562–1570
   Google Scholar
• . Rolin B, Larsen MO, Gotfredsen CF, . The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endorinol Metab. 2002;283(4):E745–E752
   PubMed Web of Science ®Google Scholar
• . Symlin [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; July 2009
   Google Scholar
• . Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, Cincotta A. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord. 2007;7:3
   PubMedGoogle Scholar
• . Unger J, Parkin CG. Type 2 diabetes: an expanded view of pathophysiology and therapy. Postgrad Med. 2010;122(3):145–157
   PubMed Web of Science ®Google Scholar
• . Handelsman Y, Mechanick JI, Blonde L ; AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17 ( suppl 1):1–53
   PubMedGoogle Scholar